Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.68 |
| ▸ | DDB1 | Q16531 | 14/20 | 0.68 |
| ▸ | STAT3 | P40763 | 4/20 | 0.54 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21106612 | 1.00 | CRBN (0.68) | CRBNDDB1STAT3GSPT1 | |
| SCHEMBL21107320 | 1.00 | CRBN (0.68) | CRBNDDB1STAT3GSPT1 | |
| SCHEMBL30631196 | 1.00 | CRBN (0.68) | CRBNDDB1STAT3GSPT1 | |
| SCHEMBL31710543 | 1.00 | CRBN (0.68) | CRBNDDB1STAT3GSPT1 | |
| SCHEMBL21070342 | 0.99 | CRBN (0.69) | CRBNDDB1STAT3GSPT1 | |
| SCHEMBL21071036 | 0.92 | CRBN (0.73) | CRBNDDB1GSPT1 | |
| SCHEMBL24823275 | 0.91 | CRBN (0.71) | CRBNDDB1STAT3GSPT1 | |
| SCHEMBL21106396 | 0.91 | CRBN (0.71) | CRBNDDB1STAT3GSPT1 | |
| SCHEMBL30805470 | 0.91 | CRBN (0.71) | CRBNDDB1STAT3GSPT1 | |
| SCHEMBL22276609 | 0.88 | CRBN (0.70) | CRBNDDB1STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-4121043-A1 | MDM2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |